As of 2024-12-15, the EV/EBITDA ratio of Akoya Biosciences Inc (AKYA) is -4.83. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. AKYA's latest enterprise value is 177.65 mil USD. AKYA's TTM EBITDA according to its financial statements is -36.77 mil USD. Dividing these 2 quantities gives us the above AKYA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 17.2x - 20.9x | 20.0x |
| Forward P/E multiples | 20.2x - 23.4x | 22.0x |
| Fair Price | (16.29) - (16.82) | (16.88) |
| Upside | -817.5% - -841.0% | -843.4% |
| Date | EV/EBITDA |
| 2024-12-13 | -4.83 |
| 2024-12-12 | -5.05 |
| 2024-12-11 | -5.21 |
| 2024-12-10 | -4.94 |
| 2024-12-09 | -4.79 |
| 2024-12-06 | -4.63 |
| 2024-12-05 | -4.56 |
| 2024-12-04 | -4.72 |
| 2024-12-03 | -4.72 |
| 2024-12-02 | -4.72 |
| 2024-11-29 | -4.74 |
| 2024-11-27 | -4.66 |
| 2024-11-26 | -4.74 |
| 2024-11-25 | -4.63 |
| 2024-11-22 | -4.62 |
| 2024-11-21 | -4.63 |
| 2024-11-20 | -4.68 |
| 2024-11-19 | -4.68 |
| 2024-11-18 | -4.59 |
| 2024-11-15 | -5.02 |
| 2024-11-14 | -5.99 |
| 2024-11-13 | -6.10 |
| 2024-11-12 | -6.07 |
| 2024-11-11 | -6.11 |
| 2024-11-08 | -6.04 |
| 2024-11-07 | -6.11 |
| 2024-11-06 | -6.14 |
| 2024-11-05 | -5.94 |
| 2024-11-04 | -5.30 |
| 2024-11-01 | -5.45 |
| 2024-10-31 | -5.57 |
| 2024-10-30 | -5.71 |
| 2024-10-29 | -5.61 |
| 2024-10-28 | -5.68 |
| 2024-10-25 | -5.55 |
| 2024-10-24 | -5.64 |
| 2024-10-23 | -5.55 |
| 2024-10-22 | -5.64 |
| 2024-10-21 | -5.83 |
| 2024-10-18 | -6.00 |
| 2024-10-17 | -5.90 |
| 2024-10-16 | -6.09 |
| 2024-10-15 | -5.99 |
| 2024-10-14 | -6.09 |
| 2024-10-11 | -5.82 |
| 2024-10-10 | -5.67 |
| 2024-10-09 | -5.86 |
| 2024-10-08 | -5.95 |
| 2024-10-07 | -6.10 |
| 2024-10-04 | -5.52 |